ATAI Life Sciences (NASDAQ: ATAI) is a clinical stage platform company dedicated to changing the paradigm for treating mental health disorders such as depression, anxiety, and addiction. ATAI’s portfolio focuses on disease altering therapies instead of symptom alleviating therapies, with an emphasis on psychedelic compounds that have a demonstrated track record of safety and efficacy in humans. Although ATAI is developing some assets in house, it is primarily employing a “buy and build” strategy wherein it identifies and acquires controlling stakes in early-stage companies, which then operate as subsidiaries with a shared operational backbone. The first of ATAI’s psychedelic programs was embodied in Compass Pathways (NASDAQ: CMPS), which conducted an IPO in September of 2020.

No items found.